Overactive Bladder Treatment Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028
Overactive Bladder Treatment Market |
Overactive Bladder (OAB) is a group of symptoms that includes
frequent urination, a strong need to urinate, urine leakage, and the need to
urinate at least twice every night. OAB is categorised as a condition rather
than a disease. Numerous factors, including weak pelvic muscles, nerve damage
from trauma or disease, urinary tract infections (UTI), obesity, hormonal
imbalance after menopause, drugs, caffeine, and alcohol, can cause an
overactive bladder. Among the illnesses that cause an overactive bladder
include Parkinson's disease, Multiple Sclerosis, and stroke. Therapy options
for overactive bladder include medication, surgery, Botox bladder treatment, as
well as some behavioural modifications such diet adjustments and bladder
retraining.
The main factors driving
expansion for Overactive
Bladder Treatment Market are
an increase in the elderly population and growing knowledge about treatments
for overactive bladder syndrome. For instance, 1 in 3 persons over the age of
30 worldwide experienced nocturia in 2018, according to the National
Association for Continence. Additionally, about 25 million Americans
experienced urine incontinence in 2018, according to a data released by the
U.S. Department of Health & Human Services.
The Overactive Bladder Treatment Market is anticipated to be
significantly impacted by COVID-19. This is mainly because COVID-19 recovered
patients are seeing an increase in overactive bladder symptoms. Ten to fourteen
weeks after being hospitalised with COVID-19, individuals are reported to have
de novo or increasing overactive bladder symptoms, according to the study
"Long COVID and COVID-19 Associated Cystitis (CAC)" published in
November 2021. Furthermore, the study "COVID-19 inflammation results in
urine cytokine elevation and causes COVID-19 associated cystitis (CAC)"
published in December 2020 noted that COVID-19 inflammation caused urine
cytokine elevation, which increased urination frequency and resulted in
overactive bladder disorder in COVID-19-infected patients.
In addition, the rising geriatric
population and the rising incidence of diseases like Parkinson's disease, which
causes overactive bladder disorder, are the main factors driving the Global Overactive Bladder Treatment Market. For instance, the World
Population Prospect estimates that there will be 771 million seniors worldwide
in 2022, and that number will rise to 994 million by 2030 and 1.6 billion by
2050. Since urinary incontinence typically worsens as people age, an overactive
bladder has a significant detrimental effect on the health and quality of life
of the elderly population.
Top Companies Mentioned are- Pfizer Inc., Johnson & Johnson,
Aurobindo Pharma Ltd., Astellas Pharma Inc., Merck & Co. Inc., Mylan NV,
Teva Pharmaceutical Industries Ltd., Ono Pharmaceutical Co. Ltd., Allergan,
AbbVie Inc., Sanofi, Cogentix Medical and Endo International Plc.
Comments
Post a Comment